{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:43:31Z","timestamp":1783446211072,"version":"3.55.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T00:00:00Z","timestamp":1625788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ophthalmologyscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Science"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.xops.2021.100040","type":"journal-article","created":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T01:21:17Z","timestamp":1626225677000},"page":"100040","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Phase 1 Study of THR-687, a Novel, Highly Potent Integrin Antagonist for the Treatment of Diabetic Macular Edema"],"prefix":"10.1016","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8928-5599","authenticated-orcid":false,"given":"Arshad M.","family":"Khanani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil S.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor H.","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suk J.","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn J.","family":"Jaffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Kozma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pravin U.","family":"Dugel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj K.","family":"Maturi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.xops.2021.100040_bib1","doi-asserted-by":"crossref","first-page":"e339","DOI":"10.1016\/S2214-109X(13)70113-X","article-title":"Causes of vision loss worldwide, 1990\u20132010: a systematic analysis","volume":"1","author":"Bourne","year":"2013","journal-title":"Lancet Glob Health"},{"issue":"4","key":"10.1016\/j.xops.2021.100040_bib2","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/ceo.12696","article-title":"Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review","volume":"44","author":"Ting","year":"2016","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.xops.2021.100040_bib4","unstructured":"International Diabetes Federation, International Diabetes Federation Diabetes Atlas, 9th ed., 2019, International Diabetes Federation. Available at: https:\/\/www.diabetesatlas.org\/en\/resources\/. Accessed October 30, 2020."},{"key":"10.1016\/j.xops.2021.100040_bib5","first-page":"939315","article-title":"Costs and quality of life in diabetic macular edema: Canadian Burden of Diabetic Macular Edema Observational Study (C-REALITY)","volume":"2014","author":"Gonder","year":"2014","journal-title":"J\u00a0Ophthalmol"},{"key":"10.1016\/j.xops.2021.100040_bib6","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.2147\/OPTH.S114006","article-title":"Comorbidity and health care visit burden in working-age commercially insured patients with diabetic macular edema","volume":"10","author":"Kiss","year":"2016","journal-title":"Clin Ophthalmol"},{"issue":"5","key":"10.1016\/j.xops.2021.100040_bib7","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1080\/00325481.2014.994468","article-title":"United States comparative costs and absenteeism of diabetic ophthalmic conditions","volume":"127","author":"Brook","year":"2015","journal-title":"Postgrad Med"},{"issue":"7","key":"10.1016\/j.xops.2021.100040_bib8","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.ophtha.2015.03.024","article-title":"Diabetic macular edema: pathophysiology and novel therapeutic targets","volume":"122","author":"Das","year":"2015","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.xops.2021.100040_bib9","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1177\/2474126419834711","article-title":"Evidence-based guidelines for management of diabetic macular edema","volume":"3","author":"Bakri","year":"2019","journal-title":"J\u00a0Vitreoretina Dis"},{"issue":"4","key":"10.1016\/j.xops.2021.100040_bib10","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","article-title":"Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE","volume":"119","author":"Nguyen","year":"2012","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.xops.2021.100040_bib11","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000458539","article-title":"Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA)","volume":"237","author":"Schmidt-Erfurth","year":"2017","journal-title":"Ophthalmologica"},{"issue":"1","key":"10.1016\/j.xops.2021.100040_bib12","doi-asserted-by":"crossref","first-page":"P66","DOI":"10.1016\/j.ophtha.2019.09.025","article-title":"Diabetic retinopathy Preferred Practice Pattern\u00ae","volume":"127","author":"Flaxel","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2021.100040_bib13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/OPTH.S151611","article-title":"Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients","volume":"12","author":"Ehlken","year":"2018","journal-title":"Clin Ophthalmol"},{"issue":"12","key":"10.1016\/j.xops.2021.100040_bib14","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1097\/IAE.0000000000001892","article-title":"Compliance and adherence of patients with diabetic macular edema to intravitreal anti-vascular endothelial growth factor therapy in daily practice","volume":"38","author":"Weiss","year":"2018","journal-title":"Retina"},{"issue":"1","key":"10.1016\/j.xops.2021.100040_bib15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1001\/jamaophthalmol.2015.4070","article-title":"Systemic safety of prolonged monthly anti-vascular endothelial growth factor therapy for diabetic macular edema: a systematic review and meta-analysis","volume":"134","author":"Avery","year":"2016","journal-title":"JAMA Ophthalmol"},{"issue":"10","key":"10.1016\/j.xops.2021.100040_bib16","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/j.ophtha.2013.02.034","article-title":"Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE","volume":"120","author":"Brown","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2021.100040_bib17","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12886-015-0035-x","article-title":"Systematic review and mixed treatment comparison of intravitreal aflibercept with other therapies for diabetic macular edema (DME)","volume":"15","author":"Korobelnik","year":"2015","journal-title":"BMC Ophthalmol"},{"issue":"4","key":"10.1016\/j.xops.2021.100040_bib18","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ophtha.2011.01.031","article-title":"The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema","volume":"118","author":"Mitchell","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2021.100040_bib19","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2147\/OPTH.S128509","article-title":"Anti-VEGF treatment of diabetic macular edema in clinical practice: effectiveness and patterns of use (ECHO study report 1)","volume":"11","author":"Blinder","year":"2017","journal-title":"Clin Ophthalmol"},{"issue":"3","key":"10.1016\/j.xops.2021.100040_bib20","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1001\/jamaophthalmol.2015.5346","article-title":"Persistent macular thickening after ranibizumab treatment for diabetic macular edema with vision impairment","volume":"134","author":"Bressler","year":"2016","journal-title":"JAMA Ophthalmol"},{"issue":"6","key":"10.1016\/j.xops.2021.100040_bib21","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial","volume":"123","author":"Wells","year":"2016","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.xops.2021.100040_bib22","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1001\/jamaophthalmol.2017.6565","article-title":"Persistent macular thickening following intravitreous aflibercept, bevacizumab, or ranibizumab for central-involved diabetic macular edema with vision impairment: a secondary analysis of a randomized clinical trial","volume":"136","author":"Bressler","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.xops.2021.100040_bib23","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ajo.2018.07.030","article-title":"Early response to anti-vascular endothelial growth factor and two-year outcomes among eyes with diabetic macular edema in protocol T","volume":"195","author":"Bressler","year":"2018","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"10.1016\/j.xops.2021.100040_bib24","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/j.ophtha.2014.04.024","article-title":"Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema","volume":"121","author":"Boyer","year":"2014","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.xops.2021.100040_bib25","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1097\/IAE.0000000000001004","article-title":"Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year Mead study","volume":"36","author":"Maturi","year":"2016","journal-title":"Retina"},{"issue":"9","key":"10.1016\/j.xops.2021.100040_bib26","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1080\/13543784.2020.1795639","article-title":"Anti-integrin therapy for retinovascular diseases","volume":"29","author":"Bhatwadekar","year":"2020","journal-title":"Expert Opin Invest Drugs"},{"issue":"6","key":"10.1016\/j.xops.2021.100040_bib27","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0092-8674(02)00971-6","article-title":"Integrins: bidirectional, allosteric signaling machines","volume":"110","author":"Hynes","year":"2002","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.xops.2021.100040_bib28","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00441-009-0834-6","volume":"339","author":"Barczyk","year":"2010","journal-title":"Integrins.Cell Tissue Res"},{"issue":"18","key":"10.1016\/j.xops.2021.100040_bib29","doi-asserted-by":"crossref","first-page":"9764","DOI":"10.1073\/pnas.93.18.9764","article-title":"Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases","volume":"93","author":"Friedlander","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.xops.2021.100040_bib30","first-page":"273","article-title":"Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent","volume":"5","author":"Ramakrishnan","year":"2006","journal-title":"J\u00a0Exp Ther Oncol"},{"issue":"6","key":"10.1016\/j.xops.2021.100040_bib31","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1124\/mol.105.020941","article-title":"Suppression and regression of choroidal neovascularization by systemic administration of an alpha5beta1 integrin antagonist","volume":"69","author":"Umeda","year":"2006","journal-title":"Mol Pharmacol"},{"issue":"3","key":"10.1016\/j.xops.2021.100040_bib32","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1124\/jpet.107.131656","article-title":"Studies with an orally bioavailable alpha V integrin antagonist in animal models of ocular vasculopathy: retinal neovascularization in mice and retinal vascular permeability in diabetic rats","volume":"324","author":"Santulli","year":"2008","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.xops.2021.100040_bib33","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.exer.2018.11.022","article-title":"The potent small molecule integrin antagonist THR-687 is a promising next-generation therapy for retinal vascular disorders","volume":"180","author":"Hu","year":"2019","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.xops.2021.100040_bib34","first-page":"30","article-title":"The scoop on anti-integrin therapy for DME","author":"Dugel","year":"2019","journal-title":"Retina Today"},{"issue":"6","key":"10.1016\/j.xops.2021.100040_bib35","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1080\/13543784.2020.1763953","article-title":"Risuteganib-a novel integrin inhibitor for the treatment of non-exudative (dry) age-related macular degeneration and diabetic macular edema","volume":"29","author":"Shaw","year":"2020","journal-title":"Expert Opin Invest Drugs"},{"key":"10.1016\/j.xops.2021.100040_bib36","article-title":"Randomized, prospective, double-masked, controlled phase 2B trial on the safety and efficacy of Alg-1001 (Luminate)","author":"Kaiser","year":"2018","journal-title":"in DME"},{"key":"10.1016\/j.xops.2021.100040_bib37","series-title":"SciFluor announces positive results of phase 1\/2 study of SF0166 topical ophthalmic solution in diabetic macular edema patients","author":"MacDougall Biomedical Communications","year":"2017"}],"container-title":["Ophthalmology Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914521000385?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914521000385?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T06:19:29Z","timestamp":1763014769000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666914521000385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S2666914521000385"],"URL":"https:\/\/doi.org\/10.1016\/j.xops.2021.100040","relation":{},"ISSN":["2666-9145"],"issn-type":[{"value":"2666-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 1 Study of THR-687, a Novel, Highly Potent Integrin Antagonist for the Treatment of Diabetic Macular Edema","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xops.2021.100040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the American Academy of Ophthalmology.","name":"copyright","label":"Copyright"}],"article-number":"100040"}}